Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with symptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events and liver‐related morbidity: incidence of gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of bleeding from gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Safety Any serious adverse event · adults with advanced disease for muscle weakness
1 finding from 1 review
Serious adverse events (falls) Median · older people at risk of poor health outcomes
It is very uncertain whether comprehensive Geriatric Assessment changes serious adverse events (falls) Median compared with usual care (very low certainty).
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events (adult and paediatric patients) · patients with severe sepsis or septic shock
Human recombinant activated protein C showed no clear difference in serious adverse events (adult and paediatric patients) compared with placebo (moderate certainty).
1 finding from 1 review
SAEs · participants with obesity
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Serious adverse events participant and study investigator reported · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in serious adverse events participant and study investigator reported compared with skim milk & lactose powder (low certainty).
1 finding from 1 review